Cyclophosphamide‐based hematopoietic stem cell mobilization before autologous stem cell transplantation in newly diagnosed multiple myeloma

Publisher： John Wiley & Sons Inc

E-ISSN： 1098-1101|30|3|176-182

ISSN： 0733-2459

Source： JOURNAL OF CLINICAL APHERESIS, Vol.30, Iss.3, 2015-06, pp. : 176-182

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

A Phase II trial of weekly bortezomib and dexamethasone in veterans with newly diagnosed multiple myeloma not eligible for or who deferred autologous stem cell transplantation

By  

BRITISH JOURNAL OF HAEMATOLOGY, Vol. 169, Iss. 1, 2015-04 ,pp. : 36-43

John Wiley & Sons Inc

Access to resources Recommend Favorite

Cyclophosphamide plus granulocyte‐colony stimulating factor for hematopoietic stem cell mobilization in patients with multiple myeloma

By  

JOURNAL OF CLINICAL APHERESIS, Vol. 31, Iss. 5, 2016-10 ,pp. : 423-428

John Wiley & Sons Inc

Access to resources Recommend Favorite

Bortezomib‐thalidomide‐dexamethasone versus bortezomib‐cyclophosphamide‐dexamethasone as induction therapy prior to autologous stem cell transplantation in multiple myeloma

By  

BRITISH JOURNAL OF HAEMATOLOGY, Vol. 168, Iss. 4, 2015-02 ,pp. : 605-606

John Wiley & Sons Inc

Access to resources Recommend Favorite

Comparison of biosimilar filgrastim with originator filgrastim for peripheral blood stem cell mobilization and engraftment in patients with multiple myeloma undergoing autologous stem cell transplantation

By  

TRANSFUSION, Vol. 55, Iss. 11, 2015-11 ,pp. : 2709-2713

John Wiley & Sons Inc

Access to resources Recommend Favorite

Poor peripheral blood stem cell mobilization affects long‐term outcomes in multiple myeloma patients undergoing autologous stem cell transplantation

By  

JOURNAL OF CLINICAL APHERESIS, Vol. 33, Iss. 1, 2018-02 ,pp. : 29-37

John Wiley & Sons Inc

Access to resources Recommend Favorite